Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib and Temozolomide for HLRCC
NCT04603365Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pamiparib in hereditary leiomyomatosis and renal cell cancer (HLRCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start Oct 2021; status: withdrawn.
02
Drugs
pamiparib
03
Conditions
hereditary leiomyomatosis and renal cell cancer (HLRCC)
Beyond the preview
Go deeper on NCT04603365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603365.